Contact us

Successful VLAIO R&D Grant Application!

Trince received a VLAIO R&D grant to support activities for further developing its novel intracellular delivery technology towards clinical cell-based therapeutic applications. The project runs until April 2025 and has three main objectives:
(1) Successful engineering of human T cells with large effector molecules (plasmids, mRNA and CRISPR/Cas9 RNPs) while preserving T cell fitness and therapeutic efficacy, (2) Develop a prototype device for automated high-throughput transfection of T cells based on Trince’s proprietary photoporation technology and, (3) Successful internal and external evaluation of the automated high-throughput prototype device.

White paper with Revatis

Together with Revatis, we successfully used our LumiPore transfection platform to deliver macromolecules into equine and human mesenchymal stem cells.